The groundwater management market is expected to grow at a CAGR of 4.5% during 2026–2034, driven by rising groundwater stress in urban and agricultural regions, stricter water regulation and compliance monitoring, and growing investment in smart monitoring to reduce non-revenue water and contamination risk. Groundwater management solutions help utilities, industries, and public agencies track aquifer health, control extraction, improve recharge planning, and maintain safe water quality through data-driven decision-making.
The global pneumonia therapeutics market is projected to grow at a CAGR of 8.6% from 2025 to 2033, driven by the increasing incidence of community- and hospital-acquired pneumonia, rising geriatric population, and advancements in antibiotic formulations and vaccines. Pneumonia continues to be a major cause of morbidity and mortality, especially among children under five and elderly populations. The rising prevalence of drug-resistant bacterial strains and greater awareness of early diagnosis and treatment are further boosting therapeutic demand.
The global combination vaccines market is projected to grow at a CAGR of 10.0% from 2025 to 2033, supported by rising immunization programs, growing pediatric vaccination rates, and increasing demand for cost-effective solutions that reduce the number of injections required. Combination vaccines integrate multiple antigens into a single formulation, enhancing patient compliance and coverage while lowering healthcare delivery costs. Global health organizations, government vaccination drives, and technological innovation in recombinant and conjugate platforms are fueling adoption across both pediatric and adult populations.
The global inflammatory bowel disease (IBD) treatment market is projected to grow at a CAGR of 5.5% from 2025 to 2033, driven by the rising prevalence of Crohn’s disease and ulcerative colitis, increasing diagnosis rates, and continuous innovation in biologics and advanced therapies. IBD, a chronic gastrointestinal disorder, requires long-term treatment strategies aimed at reducing inflammation, controlling symptoms, and preventing disease progression.
The global cerebral palsy treatment market is projected to grow at a CAGR of 3.0% from 2025 to 2033. Growth is driven by rising awareness of neurological disorders, increasing access to rehabilitation and pharmaceutical therapies, and supportive government and non-profit initiatives focused on pediatric neurodevelopmental conditions. Cerebral palsy (CP), a group of permanent movement disorders caused by early brain development damage, is managed primarily through pharmacological treatments, rehabilitation, and supportive care.
The global veterinary autoimmune disease therapeutics market is projected to grow at a CAGR of 6.2% from 2025 to 2033. Growth is primarily driven by the rising prevalence of autoimmune disorders in companion animals, increasing pet adoption, and heightened awareness among veterinarians and pet owners regarding early diagnosis and treatment. As autoimmune diseases in animals often lead to chronic health issues and reduced quality of life, demand for targeted and effective therapeutics is increasing.
The global varicella zoster virus (VZV) infection treatment market is projected to expand at a CAGR of 4.6% from 2025 to 2033, driven by rising vaccination programs, increasing awareness of viral infections, and growing elderly populations vulnerable to shingles. VZV, the causative agent of varicella (chickenpox) and herpes zoster (shingles), continues to present significant public health challenges, particularly in developing countries with limited vaccine penetration. Growing investments in antiviral therapies and immunization campaigns are shaping the market outlook.
The global vernal keratoconjunctivitis (VKC) market is projected to expand at a CAGR of 5.4% from 2025 to 2033, driven by rising prevalence of allergic ocular diseases, growing awareness of chronic eye conditions, and expanding access to advanced ophthalmic therapies. VKC is a recurrent, seasonally aggravated allergic eye disorder that primarily affects children and young adults, particularly in warm climates. Increasing diagnosis rates, coupled with new treatment developments targeting inflammation and allergic responses, are supporting steady market growth.
The global uterine fibroid treatment device market is projected to grow at a CAGR of 7.0% from 2025 to 2033. Growth is primarily driven by rising incidence of uterine fibroids among women of reproductive age, increasing demand for minimally invasive and non-invasive treatment options, and greater awareness regarding fibroid-related complications such as infertility, heavy bleeding, and pelvic pain. As healthcare providers aim to improve patient outcomes and reduce hospital stays, demand for innovative fibroid management technologies continues to rise across global healthcare systems.
The global ornithine transcarbamylase deficiency (OTCD) treatment market is projected to grow at a CAGR of 4.1% from 2025 to 2033. Growth is driven by increasing awareness of urea cycle disorders, rising newborn screening programs, and the development of targeted therapies that improve survival and quality of life. OTCD, a rare genetic metabolic disorder, often requires lifelong management through pharmacological treatment and dietary interventions. The market is supported by innovations in ammonia scavenging agents, expanded access to medical foods, and supportive government initiatives encouraging early diagnosis and treatment of rare diseases.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.